Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arcellx, Inc. - Common Stock
(NQ:
ACLX
)
68.51
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcellx, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
The Small-Cap M&A Boom of 2026: How $440 Billion in Dry Powder and Rate Cuts Are Remaking the Market
January 27, 2026
As of January 27, 2026, the financial landscape has undergone a dramatic transformation. After a prolonged "deal winter" that chilled the markets through 2023 and much of 2024, the small-cap sector is...
Via
MarketMinute
Topics
Artificial Intelligence
Bonds
Economy
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings
January 21, 2026
From
Arcellx, Inc.
Via
Business Wire
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
December 06, 2025
From
Arcellx, Inc.
Via
Business Wire
4 Analysts Assess Arcellx: What You Need To Know
↗
July 31, 2025
Via
Benzinga
Which stocks are experiencing notable movement on Monday?
↗
November 24, 2025
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition
November 18, 2025
From
Arcellx, Inc.
Via
Business Wire
Arcellx Provides Third Quarter 2025 Financial Results
November 05, 2025
From
Arcellx, Inc.
Via
Business Wire
(ACLX) - Analyzing Arcellx's Short Interest
↗
January 14, 2025
Via
Benzinga
In-Depth Examination Of 14 Analyst Recommendations For Arcellx
↗
December 09, 2024
Via
Benzinga
14 Analysts Have This To Say About Arcellx
↗
December 09, 2024
Via
Benzinga
Analyst Expectations For Arcellx's Future
↗
November 08, 2024
Via
Benzinga
Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition
November 03, 2025
From
Arcellx, Inc.
Via
Business Wire
Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference
September 03, 2025
From
Arcellx, Inc.
Via
Business Wire
Arcellx (ACLX) Q2 Revenue Drops 72%
↗
August 07, 2025
Via
The Motley Fool
Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights
August 07, 2025
From
Arcellx, Inc.
Via
Business Wire
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
↗
June 30, 2025
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.
Via
Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
↗
June 20, 2025
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.
Via
Investor's Business Daily
Topics
Government
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
May 21, 2025
From
Arcellx, Inc.
Via
Business Wire
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday
↗
May 21, 2025
Via
Benzinga
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
May 14, 2025
From
Arcellx, Inc.
Via
Business Wire
Arcellx Provides First Quarter 2025 Financial Results and Business Highlights
May 08, 2025
From
Arcellx, Inc.
Via
Business Wire
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday
↗
April 02, 2025
Via
Benzinga
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
March 20, 2025
From
Arcellx, Inc.
Via
Business Wire
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights
February 27, 2025
From
Arcellx, Inc.
Via
Business Wire
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
February 26, 2025
From
Arcellx, Inc.
Via
Business Wire
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
↗
February 12, 2025
Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.
Via
Benzinga
Arcellx Stock Earns 82 Relative Strength Rating
↗
December 27, 2024
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.
Via
Investor's Business Daily
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
↗
December 09, 2024
The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Via
Investor's Business Daily
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
↗
December 09, 2024
Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes.
Via
Benzinga
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
December 08, 2024
From
Arcellx, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
